Attached files
Exhibit 10.4
ACCENTIA BIOPHARMACEUTICALS, INC.
| September 30,
2010 (Unaudited) |
||||
| ASSETS |
||||
| Current assets: |
||||
| Cash and cash equivalents |
$ | 556,392 | ||
| Accounts receivable: |
||||
| Trade, net of allowance for doubtful accounts of $10,031 at June 30, 2010 and September 30, 2009 |
1,287,366 | |||
| Inventories |
417,087 | |||
| Unbilled receivables |
151,303 | |||
| Prepaid expenses and other current assets |
243,998 | |||
| Total current assets |
2,656,146 | |||
| Goodwill |
893,000 | |||
| Intangible assets |
1,083,962 | |||
| Furniture, equipment and leasehold improvements, net |
154,434 | |||
| Deferred finance costs, less current portion |
16,077 | |||
| Other assets |
216,791 | |||
| $ | 5,020,410 | |||
| LIABILITIES |
||||
| Liabilities not subject to compromise: |
||||
| Current liabilities: |
||||
| Accounts payable |
$ | 1,125,877 | ||
| Accrued expenses |
1,791,856 | |||
| Unearned revenues |
263,778 | |||
| Notes payable, related parties |
2,041,005 | |||
| Customer deposits |
134,613 | |||
| Derivative liability |
1,844,200 | |||
| Total current liabilities |
7,201,329 | |||
| Liabilities subject to compromise |
142,886,695 | |||
| Total liabilities |
150,058,024 | |||
| Commitments and contingencies |
— | |||
| Series A convertible redeemable preferred stock, $1.00 par value; 8,950 shares authorized; 7,529 shares issued and outstanding at June 30, 2010 and September 30, 2009 |
7,528,640 | |||